Clinical effectiveness of novel rosacea therapies

Feaster, Brittany; Cline, Abigail; Feldman, Steven R.; Taylor, Sarah L.

doi:10.1016/j.coph.2018.12.001

Cited by 17 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ocular rosacea affects the periocular zone, whereas erythematotelangiectatic, phytamous and papulopustular rosacea arise in the middle of the face and they primarily include telangiectasia, erythema, and flushing. 6 Primary symptoms are usually associated with secondary features such as burning, itching, and stinging sensation on the face. 7 The unknown etiology and the intrinsic heterogeneity of manifestations of rosacea have hampered the efficacy of treatments.…”

Section: Introductionmentioning

confidence: 99%

“…In fact, although several therapeutic options such as topical application of vasoconstrictive or antiinflammatory creams or laser treatments are used, a proper cure for this disorder does not exist and current treatments usually address and manage only some symptoms of the pathology. 6 Although it is not considered a severe pathology, the psycho-social impact of rosacea is often underrated; in fact, the pathology deeply impacts patients' quality of life, as the negative self-perception of the patient may lead to psychological co-morbidity. For instance, epidemiological data reported an increased depression rate among patients with rosacea.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Preliminary Clinical Evaluation of a Topical Product for Reducing Slight Rosacea Imperfections

Maggioni

Cimicata

Praticò

et al. 2020

CCID

View full text Add to dashboard Cite

Introduction: Rosacea is a chronic multifactorial skin disorder mainly affecting facial skin with an estimated prevalence of about 5% worldwide. Its main symptoms, occurring early during pathology development, are skin dehydration, redness, erythema, and telangiectasia. Given the lack of a resolutive cure, therapeutic approaches able to relieve the main symptoms are needed. Purpose: The aim of this research article is to evaluate the beneficial effect of a topical product (Serum BK46) on rosacea symptoms. Patients and Methods: A monocentric single-arm, non-blinded study was performed to assess the clinical effect of Serum BK46 in relieving the main symptoms of rosacea: skin dryness, increased trans epidermal water loss (TEWL), redness, and abnormal vascularization. Twenty patients with mild to moderate rosacea were enrolled in the study and asked to apply the product twice per day for 56 days. Skin moisturization, TEWL, and erythema index were instrumentally assessed at baseline and following 24 h and 14, 28 and 56 days of treatment. Clinical parameters, including redness and telangiectasia imperfection visibility, were evaluated on a 5-point scale by a specialized dermatologist at baseline and after 14, 28, and 56 days of treatment. Finally, the visibility of vessel diameter was evaluated at baseline and after 28 and 56 days of treatment. Results: Serum BK46 application restored skin hydration and prevented the loss of water by the skin. Long-term treatment with Serum BK46 significantly reduced skin redness, erythema index, and the visibility of telangiectasia imperfections and superficial vessels. The investigated product's clinical effect was demonstrated by both instrumental and clinical evaluation. Furthermore, Serum BK46 was completely tolerated and no adverse effects were recorded. Conclusion: The moisturizing and skin barrier restoring action of Serum BK46 has been clearly proven in patients displaying mild to moderate rosacea; thus, this product is a good candidate for rosacea treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Preliminary Clinical Evaluation of a Topical Product for Reducing Slight Rosacea Imperfections

Maggioni

Cimicata

Praticò

et al. 2020

CCID

View full text Add to dashboard Cite

show abstract

“…Additionally, there would be a benefit to pursuing efficacy and safety studies of novel rosacea treatments, such as oxymetazoline and brimonidine, or studies of traditional systemic antibiotics such as with the oral tetracyclines. At this time, these agents have not been evaluated in patients with inflammatory conditions associated with Demodex infestation (Feaster, Cline, Feldman, & Taylor, ; Korting & Schöllmann, ).…”

Section: Discussionmentioning

confidence: 99%

Treatment of Demodex ‐associated inflammatory skin conditions: A systematic review

Jacob

VanDaele

Brown

2019

Dermatologic Therapy

View full text Add to dashboard Cite

Bacterial folliculitis, rosacea, and other common skin conditions have been linked to infestation by Demodex mites (human demodicosis). Currently, there is little guidance for treatment of inflammatory conditions associated with demodicosis. Thus, the objective of this review is to evaluate the efficacy and safety of treatments utilized for Demodex infestation. PubMed (1946 to January 2019) and Embase (1947 to January 2019) were searched with the following term combinations: Demodex mites, Demodex folliculitis, demodicosis, Demodex folliculorum, or Demodex brevis and articles evaluating treatment of body surface colonization with Demodex mites were included. Common interventions used for Demodex infestation include metronidazole‐based therapies, permethrin, benzoyl benzoate, crotamiton, lindane, and sulfur. Short courses of metronidazole taken orally have shown efficacy in reducing Demodex density. Additionally, topical administration of permethrin daily or twice daily was shown to be efficacious across multiple studies. Crotamiton and benzyl benzoate were also efficacious treatments. Several therapies were associated with mild‐to‐moderate skin irritation. Due to limited data, no standard of care can be identified at this time. Efficacious treatment options may include permethrin, crotamiton, benzyl benzoate, and oral metronidazole; however, long‐term efficacy has not been established.

show abstract

“…24 Neodymium-doped, yttrium-aluminium-garnet (Nd-YAG) laser, 532 nm Potassium-Titanil-Phosphate (KTP), 595 nm PDL, IPL and dual wavelength long-pulsed 775 nm alexandrite/1,064 nm neodymium: yttrium-aluminum (LPAN) are examples of these modalities. 26,27 The most widely accepted examples of these are PDL, Nd:YAG and IPL. In a review article by Anzegruber et al, it was concluded that IPL was recommended at level A and Nd:YAG laser (including KTP) and PDL were recommended at level B.…”

Section: Telangiectasiamentioning

confidence: 99%

“…Ivermectin produces its anti-inflammatory effects via its effects on these mites. 27 Ivermectin 1% cream, is a safe and tolerable alternative 1st line treatment for PPR. 37 It is more effective for the treatment of PPR than metronidazole 0.75% cream.…”

Section: Papulopustular Lesionsmentioning

confidence: 99%

Conventional and Novel Treatment Modalities in Rosacea

Engın¹,

Özkoca²,

Kutlubay³

et al. 2020

CCID

View full text Add to dashboard Cite

Rosacea is a common skin disease that is troublesome for both the patients and the dermatologists. Erythema, telengiectasia, papulopustular changes and phymatous changes are the main problems faced by the patients and dermatologists in everyday practice. Due to the chronic and relapsing nature of the disease, patients are usually unsatisfied with conventional treatment methods. This article aims at redefining rosacea according to the 2017 consensus and reviewing the different treatment modalities for different manifestations of the disease in depth.

show abstract

Clinical effectiveness of novel rosacea therapies

Cited by 17 publications

References 20 publications

<p>A Preliminary Clinical Evaluation of a Topical Product for Reducing Slight Rosacea Imperfections</p>

<p>A Preliminary Clinical Evaluation of a Topical Product for Reducing Slight Rosacea Imperfections</p>

Treatment of Demodex ‐associated inflammatory skin conditions: A systematic review

<p>Conventional and Novel Treatment Modalities in Rosacea</p>

Contact Info

Product

Resources

About